Intravenous Ketamine Effects on Functional Neuroanatomy

• Status: Withdrawn
• Trial end date: 2020-05-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the neuroanatomical effects of ketamine treatment on patients with treatment-resistant depression. The investigators will compare the neuroimaging of patients several days before and after injection in order to assess the more durable changes induced by ketamine. In addition, changes in perfusion will be analyzed, in addition to changes in neurovascular coupling, and functional connectivity that are correlated with psychiatric measures.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Neurological Associates of West Los Angeles
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• In order for a subject to be considered for this study, the patient must have been diagnosed with treatment-resistant depression, meaning the patient failed three medications and has been suffering from moderate treatment-resistant depression for over 6 months, indicated by a Beck Depression Inventory score of 10 or above. The patient must have been prescribed ketamine as part of their treatment plan, completely independent of any research. The patient must be willing to comply with the study protocol.

Exclusion Criteria:

• In order for a subject to be considered for this study, he/she may not have any of the following:

• Advanced stages of any terminal illness or any active cancer that requires chemotherapy

• Hepatic impairment

• Significant cytopenia

• Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis

• Women who are pregnant, may become pregnant, or are breastfeeding

• Any counter indications to ketamine

• Subjects unable to give informed consent or in vulnerable categories, such as prisoners